RenovoRx's RenovoCath device gains traction with nine active commercial cancer centers.

RenovoRx, a life sciences company, announced continued commercial momentum with a growing number of US cancer centers integrating its RenovoCath device into oncology treatment programs. The number of active commercial cancer centers has increased from five in September 2025 to nine, with the addition of City of Hope Cancer Center and Moffitt Cancer Center. The RenovoCath device enables the company's TAMP therapy platform, designed to deliver chemotherapy near the tumor site, potentially enhancing effectiveness and minimizing systemic side effects.